I’m so thrilled that I’ve been on the Pazopanib Phase II Trial at Stanford for over two years now! I know that things will likely change at some point in the future, but for the time being my tumors/mets are all within the stable range. There are no new lesions. My typical markers (Chromogranin A, Serotonin, U-5HIAA, etc.) are all somewhat elevated, but relatively unchanged and stable. Stable is good. Boring is good. Life is good. All of this with just four pills at bedtime. No side effects. No drama. I still get injected every 28 days with 40mg Sandostatin LAR for symptom control. I also visit my amazing team at Stanford every four weeks, and have MRIs & CTs every three months. I’m happy to stay this course for as long as I can!
Six months have passed since I started the Pazopanib trial at Stanford. Last week I had my latest milestone appointment with Dr. Kunz. I’m very happy and relieved to report that all of my tumors are still stable, with no signs of new tumor activity. Another very boring report/visit which makes me ecstatic! So again the plan is to stay the course. Kathy asked some good questions this time out, and the answers were very interesting. I knew there were over 150 patients enrolled in this trial nationwide (we found out the actual number is 165), but what we didn’t know is that apparently I’m the only one enrolled in the study through Stanford. We’d also been told that I can stay in the study so long as the results are favorable, but this time Dr. Kunz let us know that the outer limit is five years. To maintain my current quality of life I’ll gladly do this for five years.
I have been experiencing a little breakthrough syndrome, but certainly nothing out of the ordinary for me. While I’m on 40mg LAR every 28 days, I haven’t been using rescue injections for several years. It was suggested that I go back to using them on an as-needed basis so I stocked up on some of the pre-loaded octreotide syringes. We also discussed Telotristat, an oral med that hopefully will be coming to market later this year, and can supplement LAR injections to help manage syndrome. Let’s hear it for oral meds!
I’m three months into the Pazopanib trial at Stanford with Dr. Kunz, and today was my first scan-review visit. Last week I had my usual MRIs of abdomen and pelvis, plus CT of chest. I was very pleased to learn that the scans showed no new tumors, no tumor growth, and even some minimal shrinkage (2.4%) of a couple of the larger “index” tumors in my liver. Woohoo! A very boring report, and as anyone with NETs can tell you: boring is good! I’m feeling pretty good on a regular basis, and my quality of life is good, so this really is welcome news. The only recent hiccup was over-eating on Thanksgiving which caused a lot of pain and made me feel awful, but that was self-inflicted so all is good.
The plan moving forward is to stay on the blinded trial for three more months. Given the promising results the presumption, or at least the hope, is that I’m actually on the med and not a placebo. I’ll continue with follow-up visits every four weeks, and then another round of scans in three months.
We’ll also be seeing Dr. Kunz and several other NETs specialists on January 24 at the 2016 Neuroendocrine Tumor Patient Conference at the UCSF Mission Bay Conference Center. This is an excellent event with lots of good information. Kathy and I have attended annually and are always glad we did. If you’re in the Bay Area that weekend I strongly encourage you to attend. Admission is free, but you need to register online in advance. Hope to see you there. Happy Holidays!